MA32416B1 - 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation - Google Patents

7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation

Info

Publication number
MA32416B1
MA32416B1 MA33457A MA33457A MA32416B1 MA 32416 B1 MA32416 B1 MA 32416B1 MA 33457 A MA33457 A MA 33457A MA 33457 A MA33457 A MA 33457A MA 32416 B1 MA32416 B1 MA 32416B1
Authority
MA
Morocco
Prior art keywords
indoles
sulfinymethyl
sulfanylmethyl
sulfonylmethyl
substituted
Prior art date
Application number
MA33457A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Kolkhof
Astrid Brüns
Kai Thede
Karl-Heinz Schlemmer
Alexander Hillisch
Dieter Lang
Michael Gerisch
Andreas Göller
Rolf Grosser
Carsten Schmeck
Elisabeth Woltering
Olaf Prien
Holger Paulsen
Armin Kern
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA32416B1 publication Critical patent/MA32416B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention porte sur de nouveaux dérivés de 7-sulfanylméthyl-, 7-sulfinylméthyl- et 7-sulfonylméthyl-indoles, sur des procédés pour les préparer, sur leur utilisation à titre individuel ou en combinaison pour le traitement et/ou la prévention de maladies, ainsi que sur leur utilisation pour préparer des médicaments destinés au traitement et/ou à la prévention de maladies, en particulier au traitement et/ou à la prévention de maladies cardiovasculaires.
MA33457A 2008-06-25 2010-12-23 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation MA32416B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008030207A DE102008030207A1 (de) 2008-06-25 2008-06-25 Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung
PCT/EP2009/004305 WO2009156072A1 (fr) 2008-06-25 2009-06-16 7-sulfanylméthyl-, 7-sulfinylméthyl- et 7-sulfonylméthyl-indoles substitués et leur utilisation

Publications (1)

Publication Number Publication Date
MA32416B1 true MA32416B1 (fr) 2011-06-01

Family

ID=41017186

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33457A MA32416B1 (fr) 2008-06-25 2010-12-23 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation

Country Status (24)

Country Link
US (2) US20110201564A1 (fr)
EP (1) EP2300423A1 (fr)
JP (1) JP2011525504A (fr)
KR (1) KR20110023895A (fr)
CN (1) CN102131776A (fr)
AR (1) AR072202A1 (fr)
AU (1) AU2009262582A1 (fr)
BR (1) BRPI0915405A2 (fr)
CA (1) CA2729048A1 (fr)
CL (1) CL2010001508A1 (fr)
CO (1) CO6321237A2 (fr)
CR (1) CR11869A (fr)
DE (1) DE102008030207A1 (fr)
DO (1) DOP2010000400A (fr)
EC (1) ECSP10010711A (fr)
IL (1) IL209718A0 (fr)
MA (1) MA32416B1 (fr)
MX (1) MX2010014447A (fr)
PE (1) PE20110331A1 (fr)
RU (1) RU2011102472A (fr)
SV (1) SV2010003773A (fr)
TW (1) TW201012800A (fr)
UY (1) UY31903A (fr)
WO (1) WO2009156072A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137220A1 (fr) * 2010-04-28 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antagonistes à petite molécule du neuropeptide s destinés au traitement d'une toxicomanie ou de troubles de l'humeur, de l'anxiété et du sommeil
RU2598842C2 (ru) 2011-01-20 2016-09-27 Мерк Шарп Энд Домэ Корп. Антагонисты рецептора минералокортикоидов
DE102011015126B4 (de) * 2011-03-25 2014-09-25 Airbus Operations Gmbh Flugzeugheckbereich mit einem in dem Flugzeugheckbereich installierten Kühlsystem
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
KR101894091B1 (ko) * 2018-01-23 2018-08-31 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN111039873B (zh) * 2019-12-20 2022-03-15 河北美荷药业有限公司 一种芬苯达唑亚砜的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2778819A (en) 1950-08-21 1957-01-22 Bayer Ag 1-alkoxy-3 imino-isoindolenine derivatives
NL82464C (fr) 1952-01-05
US2765320A (en) 1954-09-03 1956-10-02 Pittsburgh Plate Glass Co Preparation of 2, 3-dimethylindole
WO1990005721A1 (fr) 1988-11-14 1990-05-31 The Upjohn Company Acides alpha-amino-indole-3-acetiques utiles en tant qu'agents anti-diabetiques, anti-obesite et anti-athero-sclerotiques
GB9609641D0 (en) 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
WO1998006725A1 (fr) 1996-08-13 1998-02-19 Merck & Co., Inc. Indolisation catalysee au palladium
US5808064A (en) 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CN1742007A (zh) 2003-01-22 2006-03-01 伊莱利利公司 甾族激素核受体的吲哚衍生物调控剂
BRPI0507657A (pt) 2004-03-03 2007-07-10 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
WO2005118539A1 (fr) 2004-06-01 2005-12-15 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles utiles comme inhibiteurs de la reabsorption de la monoamine
US20100190768A1 (en) 2005-09-30 2010-07-29 Dainippon Sumitomo Pharma Co., Ltd. Novel fused pyrole derivative
ATE517086T1 (de) 2005-11-30 2011-08-15 Hoffmann La Roche Verfahren zur synthese von 3-amino-1- arylpropylindolen
US7960544B2 (en) 2005-12-16 2011-06-14 Ironwood Pharmaceuticals, Inc. Useful indole compounds
SG176477A1 (en) 2006-08-07 2011-12-29 Ironwood Pharmaceuticals Inc Indole compounds
US20090118503A1 (en) 2007-06-20 2009-05-07 Kevin Sprott Faah inhibitors

Also Published As

Publication number Publication date
US8063234B2 (en) 2011-11-22
AR072202A1 (es) 2010-08-11
US20110201564A1 (en) 2011-08-18
DOP2010000400A (es) 2011-01-31
IL209718A0 (en) 2011-02-28
CL2010001508A1 (es) 2011-05-06
CA2729048A1 (fr) 2009-12-30
US20100105744A1 (en) 2010-04-29
WO2009156072A1 (fr) 2009-12-30
AU2009262582A1 (en) 2009-12-30
SV2010003773A (es) 2011-08-29
EP2300423A1 (fr) 2011-03-30
RU2011102472A (ru) 2012-07-27
MX2010014447A (es) 2011-01-21
CO6321237A2 (es) 2011-09-20
JP2011525504A (ja) 2011-09-22
BRPI0915405A2 (pt) 2015-11-03
KR20110023895A (ko) 2011-03-08
CR11869A (es) 2011-05-10
TW201012800A (en) 2010-04-01
ECSP10010711A (es) 2011-01-31
UY31903A (es) 2010-01-29
DE102008030207A1 (de) 2009-12-31
CN102131776A (zh) 2011-07-20
PE20110331A1 (es) 2011-06-22

Similar Documents

Publication Publication Date Title
EA201001639A1 (ru) Композиции и способы их получения и применения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
WO2012062925A3 (fr) Composés et procédés de traitement de la douleur
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MX385174B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201170349A1 (ru) Модуляторы mif
UA102065C2 (xx) Заміщені 4-арил-1,4-дигідро-1,6-нафтиридинаміди і їх застосування$замещенные 4-арил-1,4-дигидро-1,6-нафтиридинамиды и их применение
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
WO2009026657A8 (fr) Agonistes flavonoïdes de ppar
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
EA201201623A1 (ru) Лечение диабета 2 типа
EA201190312A1 (ru) Замещенные пиперидины
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists